Core Viewpoint - The company has received FDA approval for its self-developed HLX15-SC, a subcutaneous injection of a recombinant anti-CD38 fully human monoclonal antibody, for the treatment of multiple myeloma, marking a significant milestone in its clinical development pipeline [1][2]. Group 1: Product Development - HLX15-SC is a biosimilar to Daratumumab, designed for treating multiple myeloma, which works by binding to CD38 on tumor cells and inducing apoptosis through various immune mechanisms [2]. - The company successfully completed a Phase I clinical study of HLX15-IV (intravenous formulation) in healthy male subjects in China in June 2024 [2]. - The IND application for HLX15-SC was approved by the National Medical Products Administration (NMPA) in February 2026 [2]. Group 2: Licensing and Commercialization - In February 2025, the company entered into a licensing agreement with Dr. Reddy's Laboratories Ltd., granting exclusive rights for the commercialization of HLX15 in the U.S. and specified European regions, including 42 countries [2]. Group 3: Market Potential - According to IQVIA MIDASTM, the global sales of Daratumumab are projected to be approximately $12.88 billion in 2024, indicating a substantial market opportunity for HLX15 [3].

Core Viewpoint - The stock price of Valiant Bio-B (09887) increased by 7.91% to HKD 66.20, with a trading volume of HKD 28.44 million following the announcement of its inclusion in the Hang Seng Composite Index [5]. Group 1: Stock Performance - Valiant Bio-B's stock price rose by 7.91% to HKD 66.20 [5]. - The trading volume reached HKD 28.44 million [5]. Group 2: Index Inclusion - On February 13, the Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, including Valiant Bio-B in the Hang Seng Composite Index [5]. - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026 [5]. - The inclusion may lead to adjustments in the Hong Kong Stock Connect investment scope, as Valiant Bio-B meets various criteria such as market capitalization, liquidity, and listing duration [5]. Group 3: Clinical Research - Valiant Bio-B announced the successful administration of its drug, ViliXin™ (PD-L1/4-1BB bispecific antibody, LBL-024), to the first patient in an Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [5]. - The open-label, multicenter Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted at multiple hospitals nationwide [5]. - The trial aims to evaluate the efficacy and safety of ViliXin™ either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [5].

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) experienced a significant stock price increase, rising over 17% at one point and closing up 8.6% at HKD 3.03, with a trading volume of HKD 26.6484 million [1] - On February 16, Beihai Kangcheng announced a placement of 84.0336 million new shares to a wholly-owned subsidiary of WuXi Biologics, representing approximately 14.12% of the company's enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with approximately 60% allocated for settling the group's trade payables, around 28% for research and development expenses for existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1]

Group 1 - The core point of the article is that Beihai Kangcheng-B (01228) announced a share placement to WuXi Biologics, leading to a significant increase in its stock price [1] - The company plans to issue 84.03 million new shares, representing approximately 14.12% of the enlarged issued share capital, at a price of HKD 2.38 per share, which is a discount of about 14.7% compared to the closing price of HKD 2.79 on February 13 [1] - The net proceeds from the placement are expected to reach HKD 199 million, with around 60% allocated for settling trade payables, approximately 28% for R&D expenses of existing product lines, and the remaining 12% for working capital and regulatory maintenance of commercialized products [1] Group 2 - Following the completion of the placement, WuXi Biologics' stake in Beihai Kangcheng will increase to approximately 16.27% [1]

Group 1 - The core viewpoint of the article highlights that Valiant Bio-B (09887) has seen a significant increase in stock price, rising over 6% following the announcement of its inclusion in the Hang Seng Composite Index [1] - As of the report, Valiant Bio-B's stock price is at 65.1 HKD with a trading volume of 18.6588 million HKD [1] - The inclusion in the Hang Seng Composite Index will take effect after the market closes on March 6, 2026, and will be effective from March 9, 2026, which may lead to adjustments in the Hong Kong Stock Connect investment scope [1] Group 2 - Valiant Bio-B has announced the successful administration of its drug, VILISEN™ (PD-L1/4-1BB bispecific antibody Opalizumab, LBL-024), to the first patient in a Phase Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted across multiple hospitals nationwide [1] - The trial aims to evaluate the efficacy and safety of Opalizumab either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]

每经AI快讯，2月16日，中慧生物-B(02627.HK)涨16.12%，报59.8000港元，股价创历史新高，总市值 235.28亿港元。 ...

中慧生物-B（02627）发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自2026年3月9日 起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高95%的公司， 并获指数基金、互惠基金及业绩评估系统的广泛应用。 董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 中慧生物-B（02627）发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自2026年3月9日 起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高95%的公司， 并获指数基金、互惠基金及业绩评估系统的广泛应用。 责任编辑：卢昱君 热点栏目 自选股 ...

董事会认为，本公司获纳入恒生综合指数成份股，反映资本市场对本公司业务表现及增长前景的认同。 董事会相信，此次纳入将有助于扩大本公司股东基础，提升H股的交易流通性，并进一步增强本公司的 声誉及品牌知名度。 智通财经APP讯，中慧生物-B(02627)发布公告，本公司H股已获选定并将纳入恒生综合指数成份股，自 2026年3月9日起生效。恒生综合指数作为全面的H股指标，涵盖在香港交易所主板上市的累计市值最高 95%的公司，并获指数基金、互惠基金及业绩评估系统的广泛应用。 ...

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Progress - The Phase II clinical trial for CS2009 is actively enrolling participants in Australia and China, encompassing 15 monotherapy/combinatorial regimens and 9 solid tumor indications, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] - Preliminary data from the Phase I clinical study of CS2009 has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming ASCO and ESMO meetings [1] Group 2: Company Leadership Insights - The CEO and President of R&D at the company expressed satisfaction with the efficient advancement of the global Phase II clinical trial and the FDA's approval, highlighting the positive communication and collaboration with the FDA [2] - The approval was based on the FDA's recognition of the good safety and anti-tumor activity demonstrated in the Phase I trial, confirming the research plan for the Phase II trial, including dose optimization strategies and other core elements [2]

Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1][2] Group 1: Clinical Trial Details - CS2009 is undergoing a Phase II clinical trial for advanced solid tumors, with active enrollment in Australia and China [1] - The trial includes 15 monotherapy/combo therapy regimens and 9 solid tumor indications, such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), triple-negative breast cancer (TNBC), extensive-stage small cell lung cancer (ES-SCLC), and platinum-resistant ovarian cancer (PROC) [1] - Preliminary data from the Phase I clinical study has shown good safety and tolerability, with positive anti-tumor activity results expected to be presented at the upcoming ASCO and ESMO meetings [1] Group 2: Company Statements - The CEO of the company expressed satisfaction with the efficient progress of the Phase II clinical trial and the FDA's approval, highlighting the positive communication between the company and the FDA [2] - The approval was based on the FDA's recognition of the good safety and anti-tumor activity demonstrated in the Phase I trial, confirming the study design for the Phase II trial [2] - The company is committed to advancing the global clinical development of CS2009 and anticipates sharing more positive data and research progress soon [2]